WallStSmart

Avantor Inc (AVTR)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 904% more annual revenue ($65.77B vs $6.55B). MRK leads profitability with a 13.6% profit margin vs -8.4%. MRK earns a higher WallStSmart Score of 50/100 (D+).

AVTR

Hold

37

out of 100

Grade: F

Growth: 4.7Profit: 3.5Value: 6.0Quality: 5.0
Piotroski: 3/9Altman Z: 1.32

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVTRUndervalued (+23.3%)

Margin of Safety

+23.3%

Fair Value

$12.57

Current Price

$14.38

$1.81 discount

UndervaluedFair: $12.57Overvalued
MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$129.79

$48.56 premium

UndervaluedFair: $81.23Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVTR1 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

AVTR4 concerns · Avg: 2.8/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-9.9%2/10

ROE of -9.9% — below average capital efficiency

EPS GrowthGrowth
-33.3%2/10

Earnings declined 33.3%

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AVTR

The strongest argument for AVTR centers on Price/Book.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : AVTR

The primary concerns for AVTR are Revenue Growth, Piotroski F-Score, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

AVTR profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

AVTR carries more volatility with a beta of 0.94 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 37/100). AVTR offers better value entry with a 23.3% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Avantor Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Avantor, Inc. provides products and services to clients in the biopharmaceutical, healthcare, education and government, advanced technologies and applied materials industries in America, Europe, Asia, the Middle East and Africa. The company is headquartered in Radnor, Pennsylvania.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?